The PATHFINDER Study: A Feasibility Trial

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

February 19, 2020

Study Completion Date

July 7, 2020

Conditions
Coronary Artery DiseaseDelirium
Interventions
DRUG

Ropivacaine

Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision

DRUG

Ketamine

Intraoperative infusion

DRUG

Remifentanil

Intraoperative infusion

DRUG

Dexmedetomidine

Intraoperative infusion

DRUG

Rocuronium

Intraoperative intermittent bolus

DRUG

Propofol

Intraoperative infusion

DRUG

Sevoflurane

Intraoperative inhaled as needed

DRUG

Dexmedetomidine

Post-operative infusion

DRUG

Propofol

Post-operative infusion

DEVICE

EEG monitoring

Perioperative monitoring

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER

NCT04016740 - The PATHFINDER Study: A Feasibility Trial | Biotech Hunter | Biotech Hunter